PACS Group, Inc. (NYSE: PACS) (“PACS” or the “Company”), today announced that on November 20, 2024 it received a written Filing Delinquency Notificati ...
Authorization is based on results from the Phase 3 CARTITUDE-4 (MMY3002) study, which showed treatment with CARVYKTI® reduced the risk of disease progression or death by 74 per cent compared to ...